Achilles Therapeutics PL-ADRACHL
13F holders, Q1 2026 (March 31)3holders +1
1new positions
0sold out
$1.48avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Achilles Therapeutics PL-ADR (ACHL) in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Trium Capital LLP ($46K), Rhumbline Advisers ($7K) and GAMMA Investing LLC ($1K).
- Company
- Achilles Therapeutics PL-ADR
- CUSIP
- 00449L102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $46K |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 30,753 shares bought, net +30,753 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Trium Capital LLP | 0.03% | New | 30,753 | $46K |
| Rhumbline Advisers | 0.00% | No change | 4,480 | $7K |
| GAMMA Investing LLC | 0.00% | No change | 806 | $1K |
"% of holder's portfolio" is ACHL's weight in each manager's 13F, not the share of Achilles Therapeutics PL-ADR the manager owns.